Our customers use our (cell) models because they represent a diversity of the disease that has been unattainable to date. It allows drug and cancer researchers to make better decisions about which populations of patients are more likely to respond effectively to drugs that are under investigation.
David Deems, CEO
Transforming the Search for Personalized Therapies
Cellaria Cell Models
Cellaria’s in vitro cancer cell models are derived directly from patient tumors to reflect the unique nature and complexity of each patient’s disease.
Our models are traceable back to initial patient tumor and clinical conditions, simplifying the analysis of patient-specific responses.
Cellaria Media
Our Renaissance Essential Tumor MediumTM utilizes a simple, feeder-free protocol for multiple solid tumor types including breast, lung, colon, and ovarian. Our WIT Culture Media are optimized for the expansion of normal human mammary epithelial cells and are completely defined and serum-free.
Control Products
Our RNA controls are derived from tumors that are relevant to your assay, while our DNA controls mirror the mutations that are measured in your assay.
Custom Services
Cancer Cell Model Development and Stem Cell Services
With Cellaria you have a dedicated, innovative partner in cancer and stem cell research. Draw on our deep industry expertise and patient-specific cancer and iPS cell models to seek out answers to critical questions and gain a technological edge.
From custom cancer cell model development to next-generation stem cell cell services, we provide highly specialized single source solutions to support your progress—every step of the way.
Latest Technical Resources
Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeutics
New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro “avatar” clinical trials CHERRY HILL, N.J.,...
Cellaria Inc. partners with researchers at Northeastern University to advance new photomedicine therapies for key cancers
Successful award of NIH R01 funding paves the way for accelerated Precision Therapeutics. 11/17/2020 WAKEFIELD, MA: Cellaria Inc (Wakefield, MA,...
Cellaria Inc. Introduces A New Generation Of Cell Line Models For Pancreatic Cancer Paving The Way For Better Treatment
Delivering stable, authenticated, patient-specific cell platforms for more reproducible, clinically relevant research. 09/29/2020 WAKEFIELD, MA:...
Connect With Us
Learn more about how Cellaria can help transform your research efficacy.